4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kura Oncology, Inc. (KURA) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 260 employees. Its market capitalization is roughly $964 million. In the fiscal year ended 2025-12-31, KURA reported $68M in revenue and ($279M) in net income.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Interactive charts & full statements → Open the KURA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $68M | $54M | $0M | $0M |
| Gross Profit | $67M | $54M | $0M | — |
| Operating Income (EBIT) | ($304M) | ($193M) | ($166M) | ($140M) |
| Net Income | ($279M) | ($174M) | ($153M) | ($136M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $18M | $17M | $21M | $15M | $14M |
| Gross Profit | $18M | — | — | — | $14M |
| Operating Income (EBIT) | ($79M) | ($86M) | ($80M) | ($73M) | ($65M) |
| Net Income | ($73M) | ($81M) | ($74M) | ($66M) | ($57M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $738M | $760M | $449M | $456M | — |
| Total Liabilities | $564M | $346M | $52M | $36M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KURA viewer.
About TickerBase · Data methodology & sources